Literature DB >> 21743486

Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes.

Hong Zhou1, Yong-jun Li, Mian Wang, Li-hui Zhang, Bing-yan Guo, Zhan-sheng Zhao, Feng-ling Meng, Yong-gui Deng, Rui-ying Wang.   

Abstract

AIM: To investigate whether activation of RhoA/Rho kinase (ROCK) is involved in myocardial fibrosis in diabetic hearts.
METHODS: A rat model of type 2 diabetes was established using high fat diet combined with streptozotocin (30 mg/kg, ip). Animals were randomly divided into 3 groups: control rats, untreated diabetic rats that received vehicle and treated diabetic rats that received Rho-kinase inhibitor fasudil hydrochloride hydrate (10 mg·kg(-1)·d(-1), ip, for 14 weeks). Cardiac contractile function was evaluated in vivo. The morphological features of cardiac fibrosis were observed using immunohistochemistry and TEM. The mRNA expression of JNK, TGFβ1, type-I, and type-III procollagen was assessed with RT-PCR. The phosphorylation of MYPT1, JNK and Smad2/3, as well as the protein levels of TGFβ1 and c-Jun, were evaluated using Western blotting.
RESULTS: In untreated diabetic rats, myocardial fibrosis was developed and the heart contractility was significantly reduced as compared to the control rats. In the hearts of untreated diabetic rats, the mRNA expression level and activity of JNK were upregulated; the expression of TGFβ1 and phosphorylation of Smad2/3 were increased. In the hearts of treated diabetic rat, activation of JNK and TGFβ/Smad was significantly decreased, myocardial fibrosis was reduced, and cardiac contractile function improved.
CONCLUSION: The data suggest that fasudil hydrochloride hydrate ameliorates myocardial fibrosis in rats with type 2 diabetes at least in part through inhibiting the JNK and TGFβ/Smad pathways. Inhibition of RhoA/ROCK may be a novel therapeutic target for prevention of diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21743486      PMCID: PMC4002528          DOI: 10.1038/aps.2011.54

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  47 in total

Review 1.  Rocks: multifunctional kinases in cell behaviour.

Authors:  Kirsi Riento; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

2.  Cell proliferation induced by reactive oxygen species is mediated via mitogen-activated protein kinase in Chinese hamster lung fibroblast (V79) cells.

Authors:  Min-Joon Han; Bu-Yeo Kim; Sang-Oh Yoon; An-Sik Chung
Journal:  Mol Cells       Date:  2003-02-28       Impact factor: 5.034

3.  Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts.

Authors:  Naohiko Kobayashi; Shigeo Horinaka; Shin-ichiro Mita; Shigefumi Nakano; Takeaki Honda; Kohtaro Yoshida; Tsutomu Kobayashi; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2002-09       Impact factor: 10.787

4.  Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.

Authors:  Alex Tzanidis; Ross D Hannan; Walter G Thomas; Döne Onan; Dominic J Autelitano; Fiona See; Darren J Kelly; Richard E Gilbert; Henry Krum
Journal:  Circ Res       Date:  2003-07-03       Impact factor: 17.367

5.  Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats.

Authors:  Toshio Nishikimi; Kazumi Akimoto; Xin Wang; Yosuke Mori; Kazuyoshi Tadokoro; Yayoi Ishikawa; Hiroaki Shimokawa; Hidehiko Ono; Hiroaki Matsuoka
Journal:  J Hypertens       Date:  2004-09       Impact factor: 4.844

6.  Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats.

Authors:  Thien T Tran; Neehar Gupta; Tracy Goh; Dinaz Naigamwalla; Marie C Chia; Niloofar Koohestani; Shruti Mehrotra; Gail McKeown-Eyssen; Adria Giacca; W Robert Bruce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-01       Impact factor: 4.254

7.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

8.  Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes.

Authors:  F L Norby; N S Aberle; J Kajstura; P Anversa; J Ren
Journal:  J Endocrinol       Date:  2004-01       Impact factor: 4.286

9.  The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis.

Authors:  Maria Julia Marinissen; Mario Chiariello; Tamara Tanos; Ora Bernard; Shuh Narumiya; J Silvio Gutkind
Journal:  Mol Cell       Date:  2004-04-09       Impact factor: 17.970

10.  Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.

Authors:  Kazuhiro Yamamoto; Tohru Masuyama; Yasushi Sakata; Nagahiro Nishikawa; Toshiaki Mano; Junichi Yoshida; Takeshi Miwa; Motoaki Sugawara; Yukihiro Yamaguchi; Tomomi Ookawara; Keiichiro Suzuki; Masatsugu Hori
Journal:  Cardiovasc Res       Date:  2002-07       Impact factor: 10.787

View more
  33 in total

1.  High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling.

Authors:  Amar B Singh; Rakeshwar S Guleria; Irina T Nizamutdinova; Kenneth M Baker; Jing Pan
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

2.  Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.

Authors:  Amal Hofni; Basim A Shehata Messiha; Safwat A Mangoura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-11       Impact factor: 3.000

3.  Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study.

Authors:  Rong Guo; Yang Su; Jing Yan; Hui Sun; Jiakang Wu; Weijing Liu; Yawei Xu
Journal:  Heart Vessels       Date:  2014-01-05       Impact factor: 2.037

Review 4.  Pericytes, microvasular dysfunction, and chronic rejection.

Authors:  Malgorzata Kloc; Jacek Z Kubiak; Xian C Li; Rafik M Ghobrial
Journal:  Transplantation       Date:  2015-04       Impact factor: 4.939

Review 5.  Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy.

Authors:  Mark T Waddingham; Amanda J Edgley; Hirotsugu Tsuchimochi; Darren J Kelly; Mikiyasu Shirai; James T Pearson
Journal:  World J Diabetes       Date:  2015-07-10

6.  RhoA/ROCK inhibition improves the beneficial effects of glucocorticoid treatment in dystrophic muscle: implications for stem cell depletion.

Authors:  Xiaodong Mu; Ying Tang; Koji Takayama; Wanqun Chen; Aiping Lu; Bing Wang; Kurt Weiss; Johnny Huard
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

7.  Sucrose Nonfermenting-Related Kinase Enzyme-Mediated Rho-Associated Kinase Signaling is Responsible for Cardiac Function.

Authors:  Stephanie M Cossette; Vijesh J Bhute; Xiaoping Bao; Leanne M Harmann; Mark A Horswill; Indranil Sinha; Adam Gastonguay; Shabnam Pooya; Michelle Bordas; Suresh N Kumar; Shama P Mirza; Sean P Palecek; Jennifer L Strande; Ramani Ramchandran
Journal:  Circ Cardiovasc Genet       Date:  2016-10-25

8.  RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice.

Authors:  Xiaodong Mu; Arvydas Usas; Ying Tang; Aiping Lu; Bing Wang; Kurt Weiss; Johnny Huard
Journal:  FASEB J       Date:  2013-05-23       Impact factor: 5.191

9.  Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2.

Authors:  Hesham Soliman; Anthony Gador; Yi-Hsuan Lu; Guorong Lin; Girish Bankar; Kathleen M MacLeod
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-03       Impact factor: 4.733

Review 10.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities.

Authors:  Michele Cavalera; Junhong Wang; Nikolaos G Frangogiannis
Journal:  Transl Res       Date:  2014-05-10       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.